MOSCOW, January 12 - RIA Novosti. The emergence of more infectious strains of SARS-CoV-2 requires adding to the strategy of combating the pandemic the creation of complex drugs that will protect against complications of the blood coagulation system and the human immune system, Doctor of Biological Sciences, Professor, Chief Researcher of the Institute for Biological Problems of the Cryolithozone of the Federal Research Center "Yakutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences" Boris Kershengolts.
The scientist recalled that SARS-CoV-2 has an accelerated mutation. By some estimates, its mutation rate is 250 times higher than that of influenza strains. In addition, a "British" strain with an increased ability to spread has been identified.
"The global strategy to combat the COVID-19 pandemic needs some adjustment. Namely, along with the targeted application of restrictive measures and the large-scale vaccination, it seems that attention should be paid to the creation of complex drugs (preferably biologics), which, in addition to a nonspecific antiviral actions (little dependent on the characteristics of the mutant forms of the SARS-CoV-2 virus), would reduce the risks of post-viral dysfunctions of the immune system (complications of an autoimmune nature) and the blood coagulation system (the formation of microthrombi), "said Kershengolts.
He clarified that complex drugs should effectively protect those systems in the human body that are primarily affected by infection and the failure of the functioning of which leads to the most severe consequences and complications of infection, up to a lethal outcome. With COVID-19, the blood coagulation system is primarily affected, that is, the spontaneous formation of microthrombi occurs, as well as the immune system. There is a violation of the immunotolerance of the body's own cells, leading to the development of autoimmune processes, including the "cytokine storm".
The scientist cited the example of the drug "Betukladin", which is not a medicine, but is defined as a biological additive. This drug significantly reduces the risk of COVID-19 disease, facilitates the course of the disease, and also speeds up rehabilitation.
As an example, a biological product of immunomodulatory, antiviral, adaptogenic action Chaga-Betulin is also given, which is produced in the Czech Republic from the Siberian chaga mushroom and betulin extract.
Ancha Baranova, professor at the School of Systems Biology at George Mason University, explained to RIA Novosti that dietary supplements are not included in the regimens for the prevention and treatment of diseases. She noted that there are several Russian developments that can also be effective in the prevention and treatment of COVID-19.
"Everywhere, medicine is fiercely opposing any dietary supplements to be included in the official treatment protocols," Baranova said.
She explained that the difficulty in including dietary supplements in treatment regimens is due to the fact that they are difficult to patent and not allow copying of the production scheme. While modern pharmacology rests on the unique patents of complex drugs.
The latest data on the situation with COVID-19 in Russia and the world are presented on the stopkoronavirus.ru portal.